OSTX OS THERAPIES INCORPORATED revenue, earnings and financials
For the quarter ended June 30, 2026, OS THERAPIES INCORPORATED reported revenue of n/a, net income of −$8.63M and diluted EPS of −$0.20; for the fiscal year ended December 2025 revenue was n/a.
OSTX annual revenue and earnings
- Fiscal year ended Dec 2025: revenue n/a, gross profit n/a, operating income −$28.7M, net income −$28.8M (margin n/a), EPS −$0.98
- Fiscal year ended Dec 2024: revenue n/a, gross profit n/a, operating income −$6.81M, net income −$8.88M (margin n/a), EPS −$1.28
- Fiscal year ended Dec 2023: revenue n/a, gross profit n/a, operating income −$4.34M, net income −$7.79M (margin n/a), EPS −$1.46
OSTX quarterly revenue and earnings
- Quarter ended Jun 30, 2026: revenue n/a, net income −$8.63M, EPS −$0.20
- Quarter ended Mar 31, 2026: revenue n/a, net income −$10.4M, EPS −$0.27
- Quarter ended Dec 31, 2025 (from the annual report): revenue n/a, net income −$13.5M, EPS −$0.40
- Quarter ended Sep 30, 2025: revenue n/a, net income −$6.88M, EPS −$0.21
- Quarter ended Jun 30, 2025: revenue n/a, net income −$4.54M, EPS −$0.19
- Quarter ended Mar 31, 2025: revenue n/a, net income −$3.88M, EPS −$0.18
- Quarter ended Dec 31, 2024 (from the annual report): revenue n/a, net income −$2.99M, EPS −$0.59
- Quarter ended Sep 30, 2024: revenue n/a, net income −$2.88M, EPS −$0.18
- Quarter ended Jun 30, 2024: revenue n/a, net income −$1.56M, EPS −$0.26
- Quarter ended Mar 31, 2024: revenue n/a, net income −$1.46M, EPS −$0.25
- Quarter ended Dec 31, 2023 (from the annual report): revenue n/a, net income −$1.46M, EPS n/a
- Quarter ended Sep 30, 2023: revenue n/a, net income −$1.97M, EPS −$0.38
- Quarter ended Jun 30, 2023: revenue n/a, net income −$2.51M, EPS −$0.47
- Quarter ended Mar 31, 2023: revenue n/a, net income −$1.85M, EPS n/a
OSTX cash flow, buybacks and dividends
- Fiscal year ended Dec 2025: operating cash flow −$14.2M, share buybacks n/a
- Fiscal year ended Dec 2024: operating cash flow −$7.28M, share buybacks n/a
- Fiscal year ended Dec 2023: operating cash flow −$3.01M, share buybacks n/a
OSTX balance sheet
- Jun 30, 2026: cash n/a, total assets $9.90M, total liabilities $20.7M, shareholders' equity −$11.9M
- Mar 31, 2026: cash n/a, total assets $7.30M, total liabilities $17.1M, shareholders' equity −$10.8M
- Dec 31, 2025: cash n/a, total assets $6.84M, total liabilities $11.9M, shareholders' equity −$6.10M
- Sep 30, 2025: cash n/a, total assets $8.95M, total liabilities $4.25M, shareholders' equity $3.64M
- Jun 30, 2025: cash n/a, total assets $10.3M, total liabilities $3.56M, shareholders' equity $4.94M
- Mar 31, 2025: cash n/a, total assets $4.25M, total liabilities $3.64M, shareholders' equity −$4.19M
- Dec 31, 2024: cash n/a, total assets $5.54M, total liabilities $4.73M, shareholders' equity −$3.27M
- Sep 30, 2024: cash n/a, total assets $1.98M, total liabilities $2.68M, shareholders' equity −$707K
Is OSTX profitable?
No. OS THERAPIES INCORPORATED lost $39.4M over the last four quarters.
What is OSTX's EPS?
Diluted earnings per share over the last four quarters were −$1.08; −$0.20 in the latest quarter.